Incidensen af bivirkninger totalt set var tilsvarende mellem desloratadin syrup og placebogrupperne og afveg ikke signifikant fra den sikkerhedsprofil, der er set hos voksne patienter.
The overall incidence of adverse events was similar between the desloratadine syrup and the placebo groups and did not differ significantly than the safety profile seen in adult patients.